{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105904","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.043190+00:00","generated_at":"2026-05-17T00:38:54.648303+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Q3 IMCIVREE revenue $51.3M; net loss -$0.82/sh; PDUFA Dec 20","bullets":["Q3 2025 IMCIVREE revenue $51.3M (+6% seq, +54% YoY); US $38.2M (+19% seq).","Net loss ($54.3M) or ($0.82)/share vs ($45.0M) or ($0.73)/share a year ago.","Cash and investments $416.1M at Sep 30, 2025, up from $320.6M at Dec 31, 2024.","Updated FY2025 non-GAAP operating expense guidance $295M-$315M excluding stock-based compensation.","PDUFA date Dec 20, 2025 for setmelanotide sNDA in acquired hypothalamic obesity; Phase 2 PWS data Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105904","json":"https://secwatch.observer/filing/0001104659-25-105904.json","markdown":"https://secwatch.observer/filing/0001104659-25-105904.md","text":"https://secwatch.observer/filing/0001104659-25-105904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/0001104659-25-105904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:38:54.648303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}